BridgeMD
Intranasal nafarelin compared to subcutaneous triptorelin for triggering final oocyte maturation in ovarian stimulation: a non-inferiority randomised controlled clinical trial
EU CTIS ID: 2024-516621-31-00
What this study is testing
To compare the number of metaphase II oocytes retrieved following triggering of final oocyte maturation with intranasal nafarelin compared to subcutaneous triptorelin in progesterone-primed ovarian stimulation cycles.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18- 40
- Women undergoing fertility preservation cycles with oocyte cryopreservation
- Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)
- BMI 18 – 30 kg/m2
You likely can't join if
- Allergy or hypersensitivity to either nafarelin or triptorelin
- Hypopituitarism
- Known pituitary tumour
- Contraindication to intranasal medication administration
- Previous poor response to agonist trigger
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.